ALEXION PHARM INC ALXN (NASDAQ)

(CHESHIRE, Conn. YORK)Drug developer Alexion Pharmaceuticals Inc. said Tuesday its board of directors approved a 2-for-1 stock split. The stock split, which will double the number of shares outstanding,...READ MORE

(CHESHIRE, Conn. YORK)Drug developer Alexion Pharmaceuticals Inc. said Tuesday it expects to report a profit for the next two quarters, and boosted sales guidance for its only product, Soliris.READ MORE

(NEW YORK)A surge in sales of Alexion Pharmaceuticals' rare blood disorder drug Soliris pushed the drug developer to a second-quarter profit, and boosted shares to their highest level in abo...READ MORE

(NEW YORK)Wider international expansion, the confluence of pharmacies and drug suppliers, and a more aggressive generic drug industry will be in focus at the Goldman Sachs annual health care...READ MORE

Among the premarket stories for Thursday, May 29, from AP Financial News: NEW YORK (AP)--A Stifel Nicolaus & Co. analyst upgraded SunTrust Banks Inc. on Thursday, in part because o...READ MORE

(NEW YORK)A Piper Jaffray analyst set a "Buy" rating on Alexion Pharmaceuticals Inc. Thursday, saying the company's drug Soliris could become a billion-dolar "blockbuster."READ MORE

(NEW YORK)The president and chief operating officer of biotechnology company Alexion Pharmaceuticals Inc. exercised options for 50,000 shares of common stock, according to a filing with the ...READ MORE